

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



## JACOBIO PHARMACEUTICALS GROUP CO., LTD.

加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1167)

### POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 8, 2023

At the Annual General Meeting (the “AGM”) of JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the “Company”) held on June 8, 2023, all the proposed resolutions as set out in the notice of the AGM dated May 17, 2023 were voted by way of poll. Unless the content otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Company’s circular dated May 17, 2023 (the “Circular”).

The Company’s branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, acted as the scrutineer for the vote-taking at the AGM.

As at the date of the AGM, the total number of issued shares of the Company was 793,562,280 shares, the holder of which were entitled to attend and vote at the AGM. There were no restrictions on any Shareholders to cast votes on any of the proposed resolutions at the AGM. No Shareholders were required to abstain from voting on any of the proposed resolutions at the AGM under the Listing Rules. There were no Shares entitling the holder to attend the AGM and abstain from voting in favour of any of the proposed resolutions at the AGM under Rule 13.40 of the Listing Rules. No Shareholders had stated their intention in the Circular to vote against or to abstain from voting on any of the proposed resolutions at the AGM.

The poll results in respect of all the resolutions proposed at the AGM are as follows:

ORDINARY RESOLUTIONS		NO. OF VOTES (%)	
		FOR	AGAINST
1.	To receive and adopt the audited consolidated financial statements and the reports of the directors of the Company (the “Directors”) and auditor for the year ended December 31, 2022.	348,807,751 (100.000%)	0 (0.000%)

ORDINARY RESOLUTIONS		NO. OF VOTES (%)	
		FOR	AGAINST
2.	(i) To re-elect Dr. Yinxiang WANG as an executive Director.	346,494,337 (99.337%)	2,313,414 (0.663%)
	(ii) To re-elect Ms. Xiaojie WANG as an executive Director.	343,544,941 (98.491%)	5,262,810 (1.509%)
	(iii) To re-elect Dr. Ruilin SONG as an independent non-executive Director.	346,314,641 (99.285%)	2,493,110 (0.715%)
	(iv) To re-elect Dr. Bai LU as an independent non-executive Director.	348,479,251 (99.906%)	328,500 (0.094%)
	(v) To authorize the board of Directors to fix the remuneration of the Directors.	348,807,751 (100.000%)	0 (0.000%)
3.	To re-appoint PricewaterhouseCoopers as auditor and to authorize the board of Directors to fix its remuneration.	348,791,555 (99.995%)	16,196 (0.005%)
4.	To grant a general mandate to the Directors to issue new shares of the Company not exceeding 20% of the total number of issued shares of the Company.	340,993,633 (97.760%)	7,814,118 (2.240%)
5.	To grant a general mandate to the Directors to repurchase shares of the Company not exceeding 10% of the total number of issued shares of the Company.	348,807,751 (100.000%)	0 (0.000%)
6.	To extend the general mandate to issue new shares by adding the number of shares bought-back.	340,993,633 (97.760%)	7,814,118 (2.240%)
SPECIAL RESOLUTION		NO. OF VOTES (%)	
		FOR	AGAINST
7.	To approve the adoption of the amended and restated memorandum and articles of association incorporated with the proposed amendments as set out in the Appendix III of the circular of the Company dated May 17, 2023; and authorise any one Director or the company secretary of the Company to do all such acts and things and execute all such documents on behalf of the Company as they may consider necessary, desirable or appropriate in connection with the special resolution no. 7.	348,807,751 (100.000%)	0 (0.000%)

*Notes:*

1. As more than 50% of votes were cast in favour of each of the above ordinary resolutions numbered 1 to 6, all of them were duly passed as ordinary resolutions of the Company.
2. As more than three-fourths of the votes were cast in favour of the above special resolution numbered 7, the proposed resolution numbered 7 was duly passed as a special resolution of the Company.
3. All Directors attended the AGM.

By order of the Board  
**JACOBIO PHARMACEUTICALS GROUP CO., LTD.**  
**Yinxiang WANG**  
*Chairman*

Hong Kong, June 8, 2023

*As at the date of this announcement, the Board of Directors of the Company comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Ms. Yanmin TANG, Dr. Dong LYU and Dr. Te-li CHEN as non-executive Directors, and Dr. Ruilin SONG, Dr. Ge WU and Dr. Bai LU as independent non-executive Directors.*